Tag Archives: Prime Therapeutics

April, 2018

23 April
Prime Therapeutics Finds Poor Adherence to High-Cost Multiple Sclerosis Therapy

PAUL, Minn., April 23, 2018 /PRNewswire/ — Two new studies by pharmacy benefit manager Prime Therapeutics LLC (Prime), using real-world integrated medical and pharmacy data, show members with multiple sclerosis (MS) had 8.3 times higher annual total health care expense than members without MS. More than 80 percent of the …
Share

22 March
Two Prime Therapeutics Studies Examine Diabetes Costs, How Appropriate Preventive Care Can Improve Outcomes

ST. PAUL, Minn.–(BUSINESS WIRE)–Two new studies find commercially insured members with diabetes had 2.5 times higher medical and pharmacy spending than members without diabetes matched by age, sex, state of residence and insurer. But those taking a cholesterol-lowering statin for primary prevention of heart disease – a common complication of …
Share

3 October
Prime Therapeutics Finds Autoimmune Specialty Drug Spend has Doubled

ST. PAUL, MINN. – Sept. 30, 2016 –In the past four years, spending on autoimmune drugs has doubled and utilization has jumped nearly 40 percent in a population of 4.4 million commercially-insured members, according to new research from Prime Therapeutics LLC (Prime), a pharmacy benefit manager serving more than 22 …
Share

27 September
Prime Therapeutics Research Finds Nearly Half of Members Discontinue Costly RA Drug After One Year

ST. PAUL, MINN. – Sept. 27, 2016 – Prime Therapeutics LLC (Prime), a pharmacy benefit manager serving over 22 million members nationally, analyzed members’ use of rheumatoid arthritis (RA) drug tofacitinib (Xeljanz®) to find patterns and adherence behaviors. While use of the drug had been low (one member per 100,000 …
Share

29 August
Walgreens and Prime Therapeutics Form Strategic Alliance Aimed at Lowering Costs and Improving Outcomes

Deerfield, Ill. and St. Paul, Minn. – Aug. 29, 2016 – Walgreens and Prime Therapeutics (Prime), a pharmacy benefit manager (PBM), today announced a long-term strategic alliance that includes a new retail pharmacy network agreement and the combination of the companies’ central specialty pharmacy and mail service businesses. The alliance …
Share

6 April
Prime Therapeutics’ Studies Assess Costs in Cystic Fibrosis and Hereditary Angioedema

Today, pharmacy benefit manager Prime Therapeutics LLC announced findings from two separate studies regarding the costs associated with treatment for cystic fibrosis (CF) and hereditary angioedema (HAE). According to findings from new research by Prime, ground-breaking new CF drugs that target the gene mutations causing the disease will significantly increase …
Share